SLC5A2 and type 2 diabetes mellitus: One strength of the present study is the large subset of adult patients with T2DM who received at least one dose of SGLT-2 inhibitors from a single tertiary care center, regardless of previous and/or concomitant antidiabetic agents, duration and severity of disease, comorbidities, and follow-up time.